Protagonist Therapeutics, Inc. PTGX

What this company does

Icotyde (icotrokinra) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor, which underpins the inflammatory response in psoriasis and offers potential in other IL-23-mediated diseases. Rusfertide is a first-in-class investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera. The company discovered rusfertide, advanced it into Phase 3 development, and in early 2024 entered into a co-development and co-commercialization arrangement with Takeda Pharmaceuticals, Inc. It recognizes that its success is driven by the knowledge, skills and dedication of its employees, and its human capital is fundamental to its ability to innovate and develop life-changing drug therapies. As of December 31, 2025, its total global workforce consisted of 132 full-time equivalent employees, 103 of whom were in research and development, with 123 located in the United States and 9 in Australia.

Written from the business description in Protagonist Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.